
    <!DOCTYPE html>
    <html lang="en">
    <head>
        <meta charset="UTF-8">
        <meta name="viewport" content="width=device-width, initial-scale=1">
        <title>Pharmacogenomic Report</title>
    </head>
    <body style="background-color: #fdfdfd;">
        <div style="background-color: #4CAF50; padding: 20px; box-shadow: 5px 5px 5px #888888; display: flex; align-items: center; justify-content: space-between;">
            <div style="display: flex; flex-direction: column;">
                <h1 style="font-family: Arial, sans-serif; font-size: 36px; font-weight: bold; color: #fff; text-shadow: 2px 2px #888888, 2px 2px 5px #888888; margin: 0;">Pharmacogenomic Report</h1>
                <br>
            </div>
            <img src="https://www.hbku.edu.qa/sites/default/files/media/images/hbku_2021.svg" alt="Hamad Bin Khalifa University" title="Hamad Bin Khalifa University" style="height: 100px; margin-left: 20px;">
        </div>
<p style='margin-bottom: 5px;'><b>Name: </b>Mohammed Waseem</p><p style='margin-bottom: 5px;'><b>ID: </b>10005123</p><p style='margin-bottom: 5px;'><b>Time: </b>2023-10-31 16:29:56</p><h3>Queried Genes</h3><li><a href='#results_genesymbol - diplotype'>genesymbol - diplotype</a></li><li><a href='#results_CYP2D6 - *10/*36'>CYP2D6 - *10/*36</a></li><li><a href='#results_CYP2C9 - *2/*4'>CYP2C9 - *2/*4</a></li><li><a href='#results_TPMT - *1/*1'>TPMT - *1/*1</a></li><li><a href='#results_SLCO1B1 - *1/*2'>SLCO1B1 - *1/*2</a></li><li><a href='#results_CYP2B6 - *5/*38'>CYP2B6 - *5/*38</a></li><li><a href='#results_CYP3A5 - *4/*8'>CYP3A5 - *4/*8</a></li></ul><a name='results_CYP2D6 - *10/*36'></a><div style='margin-top: 10px;'><h4>CYP2D6 - *10/*36</h4><p>Total Results: 10</p><table style='border-collapse: collapse; border: 1px solid black;'>
            <tr>
                <th style='border: 1px solid black;'>Diplotype</th>
                <th style='border: 1px solid black;'>Activity Score</th>
                <th style='border: 1px solid black;'>Phenotype</th>
                <th style='border: 1px solid black;'>EHR Priority</th>
                <th style='border: 1px solid black;'>Drug ID</th>
                <th style='border: 1px solid black;'>Drug Name</th>
                <th style='border: 1px solid black;'>Recommendation</th>
                <th style='border: 1px solid black;'>Classification</th>
            </tr>
        
            <tr>
                <td style='border: 1px solid black;'>{'CYP2D6': '*10/*36'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': '0.3'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:10324</td>
                <td style='border: 1px solid black;'>tamoxifen</td>
                <td style='border: 1px solid black;'>Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2D6': '*10/*36'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': '0.3'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:10689</td>
                <td style='border: 1px solid black;'>tramadol</td>
                <td style='border: 1px solid black;'>Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.</td>
                <td style='border: 1px solid black;'>Optional</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2D6': '*10/*36'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': '0.3'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:1455099</td>
                <td style='border: 1px solid black;'>vortioxetine</td>
                <td style='border: 1px solid black;'>Initiate therapy with recommended starting dose.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2D6': '*10/*36'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': '0.3'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:2670</td>
                <td style='border: 1px solid black;'>codeine</td>
                <td style='border: 1px solid black;'>Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2D6': '*10/*36'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': '0.3'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:3247</td>
                <td style='border: 1px solid black;'>desipramine</td>
                <td style='border: 1px solid black;'>Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
                <td style='border: 1px solid black;'>Optional</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2D6': '*10/*36'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': '0.3'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:32937</td>
                <td style='border: 1px solid black;'>paroxetine</td>
                <td style='border: 1px solid black;'>Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.</td>
                <td style='border: 1px solid black;'>Optional</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2D6': '*10/*36'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': '0.3'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:38400</td>
                <td style='border: 1px solid black;'>atomoxetine</td>
                <td style='border: 1px solid black;'>Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2D6': '*10/*36'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': '0.3'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:42355</td>
                <td style='border: 1px solid black;'>fluvoxamine</td>
                <td style='border: 1px solid black;'>Initiate therapy with recommended starting dose.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2D6': '*10/*36'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': '0.3'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:5489</td>
                <td style='border: 1px solid black;'>hydrocodone</td>
                <td style='border: 1px solid black;'>Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.</td>
                <td style='border: 1px solid black;'>Optional</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2D6': '*10/*36'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': '0.3'}</td>
                <td style='border: 1px solid black;'>{'CYP2D6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:7531</td>
                <td style='border: 1px solid black;'>nortriptyline</td>
                <td style='border: 1px solid black;'>Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            </table><a name='results_CYP2C9 - *2/*4'></a><div style='margin-top: 10px;'><h4>CYP2C9 - *2/*4</h4><p>Total Results: 9</p><table style='border-collapse: collapse; border: 1px solid black;'>
            <tr>
                <th style='border: 1px solid black;'>Diplotype</th>
                <th style='border: 1px solid black;'>Activity Score</th>
                <th style='border: 1px solid black;'>Phenotype</th>
                <th style='border: 1px solid black;'>EHR Priority</th>
                <th style='border: 1px solid black;'>Drug ID</th>
                <th style='border: 1px solid black;'>Drug Name</th>
                <th style='border: 1px solid black;'>Recommendation</th>
                <th style='border: 1px solid black;'>Classification</th>
            </tr>
        
            <tr>
                <td style='border: 1px solid black;'>{'CYP2C9': '*2/*4'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': '1.0'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:140587</td>
                <td style='border: 1px solid black;'>celecoxib</td>
                <td style='border: 1px solid black;'>Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2C9': '*2/*4'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': '1.0'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:20890</td>
                <td style='border: 1px solid black;'>lornoxicam</td>
                <td style='border: 1px solid black;'>Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2C9': '*2/*4'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': '1.0'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:37790</td>
                <td style='border: 1px solid black;'>tenoxicam</td>
                <td style='border: 1px solid black;'>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2C9': '*2/*4'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': '1.0'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:41493</td>
                <td style='border: 1px solid black;'>meloxicam</td>
                <td style='border: 1px solid black;'>Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2C9': '*2/*4'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': '1.0'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:4502</td>
                <td style='border: 1px solid black;'>flurbiprofen</td>
                <td style='border: 1px solid black;'>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2C9': '*2/*4'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': '1.0'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:5640</td>
                <td style='border: 1px solid black;'>ibuprofen</td>
                <td style='border: 1px solid black;'>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2C9': '*2/*4'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': '1.0'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:72236</td>
                <td style='border: 1px solid black;'>fosphenytoin</td>
                <td style='border: 1px solid black;'>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2C9': '*2/*4'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': '1.0'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:8183</td>
                <td style='border: 1px solid black;'>phenytoin</td>
                <td style='border: 1px solid black;'>No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            
            <tr>
                <td style='border: 1px solid black;'>{'CYP2C9': '*2/*4'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': '1.0'}</td>
                <td style='border: 1px solid black;'>{'CYP2C9': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:8356</td>
                <td style='border: 1px solid black;'>piroxicam</td>
                <td style='border: 1px solid black;'>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            </table><a name='results_CYP2B6 - *5/*38'></a><div style='margin-top: 10px;'><h4>CYP2B6 - *5/*38</h4><p>Total Results: 1</p><table style='border-collapse: collapse; border: 1px solid black;'>
            <tr>
                <th style='border: 1px solid black;'>Diplotype</th>
                <th style='border: 1px solid black;'>Activity Score</th>
                <th style='border: 1px solid black;'>Phenotype</th>
                <th style='border: 1px solid black;'>EHR Priority</th>
                <th style='border: 1px solid black;'>Drug ID</th>
                <th style='border: 1px solid black;'>Drug Name</th>
                <th style='border: 1px solid black;'>Recommendation</th>
                <th style='border: 1px solid black;'>Classification</th>
            </tr>
        
            <tr>
                <td style='border: 1px solid black;'>{'CYP2B6': '*5/*38'}</td>
                <td style='border: 1px solid black;'>{'CYP2B6': 'n/a'}</td>
                <td style='border: 1px solid black;'>{'CYP2B6': 'Intermediate Metabolizer'}</td>
                <td style='border: 1px solid black;'>Abnormal/Priority/High Risk</td>
                <td style='border: 1px solid black;'>RxNorm:195085</td>
                <td style='border: 1px solid black;'>efavirenz</td>
                <td style='border: 1px solid black;'>Consider initiating efavirenz with decreased dose of 400 mg/day</td>
                <td style='border: 1px solid black;'>Moderate</td>
            </tr>
            </table><h2>Results</h2><p>No Strong classification were found.</p><h4 style='font-size: 18px; line-height: 1.5;'><b>Summary</b></h4><p style='font-size: 16px; line-height: 1.5;'>Total Results for All Entries: 20</p><h5 style='font-size: 12px; line-height: 1;'><b>Methodology</b></h5><p style='font-size: 12px; line-height: 1;'>Genotypes were called using Aldy version 2.0.0. Actionable drug recommendations were obtained from CPIC guidelines.</p>
</body>
</html>
